Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: C01BG11

Brinavess(vernakalant hydrochloride)

Atrial Fibrillation

Marketing Authorisation Holder: Advanz Pharma Limited

EMA Authorisation: 01/09/2010

INN: vernakalant hydrochloride

Indication

Rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults: for non-surgery patients: atrial fibrillation </= 7 days duration; for post-cardiac surgery patients: atrial fibrillation </= 3 days duration.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Brinavess — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.